Evidence map›Paper›PMID 21760734›Full record

ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2011

New onset diabetes after transplantation (NODAT): an overview.

Phuong-Thu T Pham, Phuong-Mai T Pham, Son V Pham, Phuong-Anh T Pham, Phuong-Chi T Pham

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed, 4 pooled it
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 4 syntheses or guidelines pooled it, 239 citations in OpenAlex.

  1. Pooled it
  2. Prognostic impact of post-transplant diabetes mellitus in kidney allograft recipients: a meta-analysis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Challenges of calcineurin inhibitor withdrawal following combined pancreas and kidney transplantation: Results of a prospective, randomized clinical trial.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2020
    Trial
  6. Trial
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Synergistic Effect of Cytochrome P450 Family 3 Subfamily A Member 5 (ACS pharmacology & translational science · 2024
    Article
  20. Article

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Phuong-Thu T PhamNephrology Division, Kidney Transplant Program, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA;
Phuong-Mai T Pham
Son V Pham
Phuong-Anh T Pham
Phuong-Chi T Pham
Olive View-UCLA Medical Center · USUniversity of California, Los Angeles · USVA West Los Angeles Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although renal transplantation ameliorates cardiovascular risk factors by restoring renal function, it introduces new cardiovascular risks including impaired glucose tolerance or diabetes mellitus, hypertension, and dyslipidemia that are derived, in part, from immunosuppressive medications such as calcineurin inhibitors, corticosteroids, or mammalian target of rapamycin inhibitors. New onset diabetes mellitus after transplantation (NODAT) is a serious and common complication following solid organ transplantation. NODAT has been reported to occur in 2% to 53% of all solid organ transplants. Kidney transplant recipients who develop NODAT have variably been reported to be at increased risk of fatal and nonfatal cardiovascular events and other adverse outcomes including infection, reduced patient survival, graft rejection, and accelerated graft loss compared with those who do not develop diabetes. Identification of high-risk patients and implementation of measures to reduce the development of NODAT may improve long-term patient and graft outcome. The following article presents an overview of the literature on the current diagnostic criteria for NODAT, its incidence after solid organ transplantation, suggested risk factors and potential pathogenic mechanisms. The impact of NODAT on patient and allograft outcomes and suggested guidelines for early identification and management of NODAT will also be discussed.

Indexed as

cyclosporinecytomegalovirus and diabeteshepatitis C and diabetesnew onset diabetes after transplantation (NODAT)sirolimustacrolimus

Identifiers

PMID21760734
PMCPMC3131798
OpenAlexW1999249353

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.